Sharemaestro company-news research for Clinuvel Pharmaceuticals Limited (CUV), showing current tone, evidence confidence, direct company coverage, sector and industry context, completed price response and the source headlines used on the page. Scores describe published news evidence. Confidence describes the amount, freshness, source breadth and direct company relevance of that evidence. Price context is shown separately.
ASX
Australia
Provisional evidence
Company news sentiment
CUV news sentiment
Clinuvel Pharmaceuticals Limited
Company headlines from the last 30 days, weighted by freshness, relevance, publisher quality and the strength of the wording. Price is shown separately.
30-day score50Neutral is 50
Early balanced news score
15/100 evidence confidence
100% direct company focus
6 current stories across 2 publishers
Current company news
Early balanced news score
6 company-specific stories are available, but there are not yet enough fresh stories from separate publishers for a firm reading.
Observed headline tone64/100
→
Reliability-adjusted score50/100
Latest source headline
Clinuvel Pharmaceuticals (ASX:CUV) Funds Its Next Chapter From a AUD 233 Million Reserve
Kalkine · 02 Aug 2026 19:50 · Source lookup
Freshness, source quality and evidence depth temper uncertain readings toward 50; confidence remains a separate reliability measure.
What supports the score
6 current stories are mapped specifically to CUV.
What limits the score
Only 2 publishers currently contribute to the measured read.
The stories agree, but freshness-weighted evidence is only 0.015.
Evidence confidence is 15/100, below the threshold for a firm classification.
50/100
News scoreEarly balanced news score
15/100
Confidencethin evidence
100%/100
Company news6 company stories
94/100
Story agreement6/100 difference
News history
Daily score and story count over 30 days
15 Jul30 Jul13 Aug
News scoreStory count50 baseline
Confidence
How reliable the score is
Confidence uses the amount of news, separate publishers, direct company relevance, freshness and agreement. A high or low score is not automatically reliable.
Amount of evidence0
0.015 after freshness weightingSource breadth40
2 independent publishersCompany relevance100
share tied directly to this companyFreshness3
recency-weighted evidenceAgreement94
how closely stories agreePublisher mix16
less reliance on one publisherPrice and news history
News score and weekly price over 26 weeks
Company-specific news is present, but the evidence has not yet earned enough independent, fresh information weight for price confirmation to be treated as a firm signal.
One scoring method across the chart.Stored company headlines are recalculated at each weekly point with the current 30-day freshness weighting. Old published snapshots are left unchanged.
13 Feb15 May07 Aug
Weekly close, indexedSentiment score
WeekNews scoreCloseWeekly move
07 Aug 202650AUD 9.44+4.2%
31 Jul 202651AUD 9.06-9.9%
24 Jul 202652AUD 10.06+1.4%
17 Jul 202650AUD 9.92-3.4%
10 Jul 202650AUD 10.27+0.2%
03 Jul 202650AUD 10.25+2.6%
26 Jun 202650AUD 9.99-3.0%
Provisional evidence
News subjects
What is shaping the score
Market update505 stories · 83%
Regulatory and legal671 stories · 17%
Source mix
Where the evidence comes from
Kalkine663 stories · 50%
Stock Titan503 stories · 50%
Recurring subjects
Subjects appearing most often
Topic structure will appear when classified tags are present in the current feed.
Earlier readings
How the score has changed
Past and present use the same method.Each point recalculates the previous 30 days of stored company headlines with today's scoring rules. The original stored snapshots remain unchanged.
22 Jun50 neutral13 Aug 16:15
ConstructiveBalanced or withheldCautious
Changes in the stored score
Scores are rebuilt from stored headlines with the current 30-day method. Days with no change are collapsed.
| Observed | Score | Move | Confidence | Stories | Status |
|---|---|---|---|---|---|
| 13 Aug 16:15 | 50 | -1 | 16/100 (-9) | 6 (-2) | Provisional |
| 02 Aug 23:59 | 51 | +0 | 25/100 (0) | 8 (0) | Provisional |
| 01 Aug 23:59 | 51 | +0 | 25/100 (+2) | 8 (0) | Provisional |
| 31 Jul 23:59 | 51 | -1 | 23/100 (-4) | 8 (-2) | Provisional |
| 23 Jul 23:59 | 52 | +0 | 27/100 (-2) | 10 (+1) | Provisional |
| 22 Jul 23:59 | 52 | -1 | 29/100 (-2) | 9 (0) | Provisional |
| 19 Jul 23:59 | 53 | +3 | 31/100 (+7) | 9 (+1) | Provisional |
| 07 Jul 23:59 | 50 | +0 | 24/100 (-1) | 8 (+1) | Provisional |
Source headlines
The news behind the score
Only company-specific stories enter this score. The latest 30 days are shown newest first, with newer stories weighted more heavily and duplicate coverage combined.
#150Tone
KalkineDirect company coverageScored from headlineSource lookup
Clinuvel Pharmaceuticals (ASX:CUV) Funds Its Next Chapter From a AUD 233 Million Reserve
- Published
- 02 Aug 2026 19:50
- News subject
- Market update
- Why this score
- No clear positive or negative phrase
- How it is used
- Direct company coverage
- Weighted influence
- Low · 7.4% · 10.9d old
- Duplicates
- 1 consolidated
#250Tone
Stock TitanDirect company coverageScored from headlineSource lookup
Clinuvel Pharmaceuticals (OTC: CLVLF) maps vitiligo trial benchmarks and plans
- Published
- 01 Aug 2026 22:02
- News subject
- Market update
- Why this score
- No clear positive or negative phrase
- How it is used
- Direct company coverage
- Weighted influence
- Low · 5.4% · 11.8d old
- Duplicates
- 1 consolidated
#350Tone
Stock TitanDirect company coverageScored from headlineSource lookup
Clinuvel Pharmaceuticals (CLVLF) files ASX notice on cessation of securities
- Published
- 31 Jul 2026 10:31
- News subject
- Market update
- Why this score
- No clear positive or negative phrase
- How it is used
- Direct company coverage
- Weighted influence
- Low · 3.2% · 13.2d old
- Duplicates
- 1 consolidated
#450Tone
KalkineDirect company coverageScored from headlineSource lookup
Why Clinuvel Pharmaceuticals (ASX:CUV) Shares Are in Focus Today?
- Published
- 23 Jul 2026 02:36
- News subject
- Market update
- Why this score
- No clear positive or negative phrase
- How it is used
- Direct company coverage
- Weighted influence
- Low · 0.2% · 21.6d old
- Duplicates
- 1 consolidated
#550Tone
Stock TitanDirect company coverageScored from headlineSource lookup
Clinuvel Pharmaceuticals (CUVL) uplifts ADR to Level II ADS
- Published
- 22 Jul 2026 20:45
- News subject
- Market update
- Why this score
- No clear positive or negative phrase
- How it is used
- Direct company coverage
- Weighted influence
- Low · 0.2% · 21.8d old
- Duplicates
- 1 consolidated
#667Tone
KalkineDirect company coverageScored from headlineSource lookup
Clinuvel Pharmaceuticals (ASX:CUV) Wins Canadian Approval for Scenesse, Expanding Its Global Rare-Disease Footprint
- Published
- 19 Jul 2026 18:09
- News subject
- Regulatory and legal
- Why this score
- Contract or approval won
- How it is used
- Direct company coverage
- Weighted influence
- High · 83.7% · 24.9d old
- Duplicates
- 1 consolidated
Earlier company news
CUV news archive
Stored newest first for historical research. These older headlines are retained for reference and do not contribute to the current sentiment gauge above. Where an early legacy import did not retain its canonical URL, the headline links to an exact publisher-aware source lookup instead of inventing an article address.
Jul
07
2026
KalkineArchivedLegacy headline · tone unscoredLegacy source lookup
Clinuvel Pharmaceuticals (ASX: CUV): Research, Commercialisation and Pipeline Growth Drive Long-Term Strategy
- Published
- 7 Jul 2026 09:55
- Catalyst
- Legacy snapshot
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Jul
05
2026
Kalkine MediaArchivedLegacy headline · tone unscoredLegacy source lookup
ASX 200 Biotech Watch: Can Clinuvel’s Skin Study Deliver?
- Published
- 5 Jul 2026 18:34
- Catalyst
- Legacy snapshot
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Jul
03
2026
The Globe and MailArchivedLegacy headline · tone unscoredLegacy source lookup
Clinuvel Extends CEO’s Term to 2029 as Board Backs Ambitious Expansion Plan
- Published
- 3 Jul 2026 06:34
- Catalyst
- Legacy snapshot
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Jul
02
2026
TradingViewArchivedLegacy headline · tone unscoredLegacy source lookup
Price to earnings forward of Clinuvel Pharmaceuticals Limited – ASX:CUV
- Published
- 2 Jul 2026 11:19
- Catalyst
- Legacy snapshot
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Jun
28
2026
TradingViewArchivedLegacy headline · tone unscoredLegacy source lookup
Clinuvel Pharmaceuticals Limited Actuals & Estimates (ASX:CUV)
- Published
- 28 Jun 2026 11:57
- Catalyst
- Legacy snapshot
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Jun
27
2026
Motley FoolArchivedLegacy headline · tone unscoredLegacy source lookup
CRISPR Therapeutics AG vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026?
- Published
- 27 Jun 2026 11:33
- Catalyst
- Legacy snapshot
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Jun
27
2026
KalkineArchivedLegacy headline · tone unscoredLegacy source lookup
What’s Driving the Recent Drop in Clinuvel Pharmaceuticals (ASX:CUV) Shares?
- Published
- 27 Jun 2026 08:04
- Catalyst
- Legacy snapshot
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Jun
22
2026
KalkineArchivedLegacy headline · tone unscoredLegacy source lookup
Is Clinuvel Pharmaceuticals (ASX: CUV) Expanding Beyond SCENESSE®?
- Published
- 22 Jun 2026 21:27
- Catalyst
- Legacy snapshot
- Coverage
- Direct company
- Duplicates
- 1 consolidated
How the page works
How to read the score
It describes the weighted balance of qualifying headlines. A score of 50 can mean balanced news or that there is not enough evidence; the status label explains which.
Confidence measures depth, source breadth, direct relevance, freshness and agreement. It does not rise merely because the tone is extreme.
Weekly price response, trend and fair-value position test whether the market is accepting or rejecting the news. They never rewrite the news score.
It measures news already published. It is not a forecast, recommendation or price target.